Despite promising clinical evidence, copyright's Vyndamax, a therapy for hereditary transthyretin-mediated amyloidosis (hATTR), is encountering substantial difficulty from pharmacy benefit managers. These companies are typically erecting limitations to coverage, including steep price requirements